Pfizer Inc. agreed to plead guilty under a $2.3 billion federal settlement over unlawful prescription-drug promotions.The company in January disclosed it would pay the $2.3 billion over allegations it had marketed the since-withdrawn anti-inflammatory drug Bextra and possibly other products for medical conditions different than their approved use. Details of the settlement weren't available in January, however.

The final agreement, announced Wednesday, also resolves Justice Department investigations involving alleged past off-label promotional practices concerning Zyvox, Geodon and Lyrica and allegations related to certain payments to health-care professionals Pfizer medicines.

More...